Genetic insights in this article
- GLP1R (rs6923761) determines your semaglutide response. The AA genotype shows 58% faster weight loss in clinical trials compared to GG — same drug, same dose, dramatically different outcomes based on one SNP.
- PPARG (rs1801282, Pro12Ala) controls adipocyte differentiation and fat storage patterns. The Ala variant improves insulin sensitivity and predicts stronger AOD-9604 response for visceral fat reduction.
- FTO (rs9939609) is widely called the 'obesity gene' but does NOT predict peptide response. FTO affects appetite signaling, not drug metabolism — your weight loss peptide choice should ignore this variant entirely.
TL;DR
- 1.Semaglutide (GLP-1) is the most evidence-backed peptide for weight loss — but GLP1R gene variants cause a 58% difference in response speed between genotypes.
- 2.AOD-9604, MOTS-c, Tesamorelin, and CJC-1295+Ipamorelin each target fat loss through different mechanisms — your genetics determine which pathway is strongest for you.
- 3.The FTO 'obesity gene' does NOT predict peptide response — this is the most common myth in the space, and we debunk it here.
- 4.PPARG variants influence how well AOD-9604 mobilises stored fat, while MOTS-c response tracks with mitochondrial haplotype.
- 5.A genetic peptide report matches your SNPs to the right compound before you spend months on the wrong protocol.
The peptide weight loss market hit $3.2 billion in 2025 and is projected to triple by 2028. Semaglutide alone accounts for most of that — but it's far from the only compound that works, and it's not the best choice for every genotype.
Monthly searches for "peptide for weight loss" — up 396% year-on-year. Most of that traffic lands on content that ignores genetics entirely.
This guide ranks the top 5 peptides for body composition by evidence tier, explains the mechanism of each, and — critically — identifies the genetic variants that determine which one is most effective for your biology.
Most "best peptides for weight loss" articles rank compounds by popularity. We rank by clinical evidence, then layer in the genetic factors that predict your individual response. Two people can take the same peptide at the same dose and get completely different results — your DNA explains why.
What are the best peptides for weight loss in 2026?
We evaluated every peptide with weight loss data across three criteria: strength of clinical evidence, mechanism clarity, and genetic modifiability (whether known SNPs predict response). Here's the ranking:
Semaglutide (GLP-1 Receptor Agonist)
The gold standard. Semaglutide mimics GLP-1, a hormone that reduces appetite, slows gastric emptying, and improves insulin signaling. The STEP trials showed 14.9% body weight reduction over 68 weeks at 2.4 mg/week — the strongest result of any peptide.
Genetic factor: GLP1R rs6923761. The AA genotype achieves target weight 58% faster than GG in matched cohorts. This single SNP is the strongest genetic predictor of response to any weight loss peptide.
Caveat: Muscle loss (up to 40% of weight lost is lean mass without resistance training). Nausea in 44% of users during titration. Rebound weight gain after discontinuation in most studies.
AOD-9604 (Modified GH Fragment)
A modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis without the growth-promoting or diabetogenic effects of full GH. Targets fat breakdown specifically — no effect on muscle or blood sugar.
Genetic factor: PPARG rs1801282 (Pro12Ala). The Ala allele improves insulin sensitivity and fat cell responsiveness, predicting stronger lipolytic response to AOD-9604. Carriers of Pro/Pro may need higher doses or longer protocols.
Caveat: Phase II data showed statistical significance for fat loss, but the FDA did not approve it as a drug. Now available through compounding pharmacies. Evidence is moderate, not strong.
MOTS-c (Mitochondrial Peptide)
A mitochondria-derived peptide that activates AMPK — the same pathway triggered by exercise and metformin. MOTS-c improves insulin sensitivity, increases fatty acid oxidation, and may enhance exercise capacity. Think of it as an exercise mimetic at the mitochondrial level.
Genetic factor: Mitochondrial haplotype affects endogenous MOTS-c levels. East Asian haplogroups tend to have higher baseline levels. Response also correlates with AMPK pathway variants (PRKAA2).
Caveat: Limited human trial data. Most evidence is from animal models and small cohorts. Promising mechanism but early-stage for weight loss specifically.
Tesamorelin (GHRH Analog)
A growth hormone releasing hormone analog that specifically reduces visceral adipose tissue (the dangerous belly fat surrounding organs). FDA-approved for HIV-associated lipodystrophy, now used off-label for body composition. Reduces visceral fat by 15-18% over 26 weeks without affecting subcutaneous fat.
Genetic factor: GHR (growth hormone receptor) variants, particularly the d3-GHR polymorphism, affect downstream signaling from GH release. Carriers of the d3 allele show enhanced GH sensitivity and may respond more strongly to Tesamorelin's GHRH stimulation.
Caveat: Only targets visceral fat. Does not produce dramatic scale changes. Best for metabolic health improvement rather than aesthetic weight loss.
CJC-1295 + Ipamorelin (GH Secretagogue Stack)
CJC-1295 extends growth hormone releasing hormone's half-life. Ipamorelin is a selective ghrelin mimetic that triggers GH pulses without spiking cortisol or prolactin. Together, they amplify natural GH secretion — which declines ~14% per decade after age 30.
Genetic factor: GHRHR variants affect your pituitary's sensitivity to GH-releasing signals. Low-sensitivity genotypes may see blunted response from CJC-1295. GHR d3 polymorphism also relevant here.
Caveat: GH-mediated fat loss is slower and more subtle than GLP-1 agonists. Best for body recomposition (simultaneous fat loss + lean mass gain) rather than rapid weight loss. Requires consistent 5-days-on/2-off cycling.
How do weight loss peptides compare side by side?
| Peptide | Evidence Tier | Mechanism | Key Genetic Factor | FDA Status |
|---|---|---|---|---|
| Semaglutide | Strong (Phase III) | GLP-1 receptor agonism | GLP1R rs6923761 | Approved (Wegovy) |
| AOD-9604 | Moderate (Phase II) | Lipolysis via GH fragment | PPARG rs1801282 | Not approved |
| MOTS-c | Emerging | AMPK activation | Mitochondrial haplotype | Not approved |
| Tesamorelin | Strong (for visceral fat) | GHRH stimulation | GHR d3 polymorphism | Approved (Egrifta) |
| CJC-1295 + Ipamorelin | Moderate | GH secretagogue | GHRHR variants | Not approved |
This table shows why "what's the best peptide for weight loss?" has no universal answer. Semaglutide has the strongest evidence overall — but if your GLP1R genotype is GG, you may respond 58% slower than someone with AA. Meanwhile, AOD-9604 might outperform for your specific genetic profile if you carry the PPARG Ala variant.
Does the FTO "obesity gene" predict peptide response?
No. This is the most persistent myth in peptide weight loss content, and it needs to die.
Predictive value of FTO rs9939609 for semaglutide, AOD-9604, or any weight loss peptide response. FTO affects appetite regulation — not drug metabolism or receptor sensitivity.
FTO (rs9939609) does increase obesity risk by 20-30% per allele, primarily through increased appetite and reduced satiety signaling. But carrying the risk allele tells you nothing about how you'll respond to peptide therapy. The GIANT consortium meta-analysis (n=339,224) confirmed this: FTO predicts weight gain risk, not treatment response.
The variants that actually predict peptide response are receptor and metabolism genes: GLP1R for semaglutide, PPARG for AOD-9604, GHRHR for CJC-1295. These are what a genetic peptide report should test — not FTO.
Think of it this way: FTO tells you whether your body is more likely to gain weight. GLP1R tells you whether a specific drug will help you lose it. They're completely different questions. Testing FTO and choosing a peptide based on it is like checking your blood type to decide which antibiotic to take.
How does DNA determine which weight loss peptide works for you?
Every peptide in this ranking acts through a specific receptor or metabolic pathway. Your genetic variants alter those receptors and pathways — which means the same dose of the same compound produces measurably different results in different genotypes.
Do weight loss peptides cause muscle loss?
This is the critical question most guides skip. Semaglutide's STEP trials showed that up to 40% of weight lost was lean mass — a serious concern for long-term metabolic health and functional capacity.
Of weight lost on semaglutide can be lean mass — unless you combine with resistance training and adequate protein (1.6g/kg/day minimum).
The peptide you choose significantly affects your lean mass outcome:
- Semaglutide: Highest muscle loss risk. Mandatory resistance training. Protein intake critical.
- AOD-9604: Does not affect lean mass. Targets lipolysis only.
- CJC-1295 + Ipamorelin: Actually preserves and builds lean mass through GH. Ideal for recomposition.
- Tesamorelin: Visceral fat specific, lean mass neutral.
- MOTS-c: Early data suggests lean mass preservation through improved mitochondrial function.
If your primary goal is looking better and preserving muscle, semaglutide alone is actually one of the worst choices despite being the most popular. A CJC-1295 + Ipamorelin stack with moderate caloric deficit achieves slower fat loss but preserves lean mass. Your genetics, goals, and timeline should drive the choice — not the hype cycle.
Can you stack weight loss peptides together?
Yes, and strategic stacking addresses the weaknesses of individual compounds. The most evidence-based combinations:
CJC-1295 + Ipamorelin + AOD-9604
GH secretion for lean mass + targeted lipolysis. No appetite suppression (add semaglutide if needed). Best for: athletes, lifters, anyone prioritising muscle preservation. Protocol: 5 days on / 2 off cycling.
Semaglutide + CJC-1295 + Ipamorelin
GLP-1 appetite suppression + GH-mediated lean mass preservation. Addresses semaglutide's biggest weakness (muscle loss) with CJC/Ipa's biggest strength (lean mass). Requires practitioner supervision for dose management.
MOTS-c + Tesamorelin
Mitochondrial function + visceral fat reduction. Targets metabolic syndrome markers rather than scale weight. Best for: insulin resistance, visceral adiposity, metabolic health optimisation. Less data on this combination specifically.
Which weight loss peptide should you choose?
There is no single "best peptide for weight loss." Semaglutide has the strongest clinical evidence overall, but your GLP1R genotype creates a 58% variance in response speed. AOD-9604 targets fat specifically without muscle loss — but responds best in PPARG Ala carriers. CJC-1295 + Ipamorelin is the best recomposition option but the slowest for pure weight loss.
The rational approach: test the genetic variants that predict response (GLP1R, PPARG, ADRB2, MC4R), match to the compound with the strongest predicted effect for your genotype, and design a protocol around your specific goals — not someone else's results.
A genetic peptide report identifies these variants from a saliva sample or existing DNA data, ranking each weight loss peptide by your predicted genetic response before you commit to a protocol.
Your genetics affect your peptide response.
Find out which peptides align with your DNA before you start any protocol.
Frequently asked questions
What is the most effective peptide for weight loss?
Semaglutide (a GLP-1 receptor agonist) has the strongest clinical evidence, with Phase III trials showing 14.9% body weight reduction over 68 weeks. However, effectiveness varies significantly by genotype — GLP1R rs6923761 AA carriers lose weight 58% faster than GG carriers on the same dose. AOD-9604 and CJC-1295 + Ipamorelin are better options for specific genetic profiles or body recomposition goals.
Does the FTO gene affect how well weight loss peptides work?
No. FTO (rs9939609) increases obesity risk through appetite signaling but has zero predictive value for peptide response. The genes that actually predict weight loss peptide effectiveness are GLP1R (for semaglutide), PPARG (for AOD-9604), and GHRHR (for CJC-1295). Testing FTO to choose a peptide is scientifically unsupported.
Do weight loss peptides cause muscle loss?
Semaglutide can cause significant muscle loss — up to 40% of weight lost may be lean mass without resistance training and adequate protein (1.6g/kg/day). AOD-9604 does not affect lean mass. CJC-1295 + Ipamorelin actually preserves and builds muscle through growth hormone stimulation, making it the best choice for body recomposition.
Can you stack multiple weight loss peptides?
Yes. The most evidence-based stack is semaglutide + CJC-1295/Ipamorelin, which combines GLP-1 appetite suppression with GH-mediated lean mass preservation. For body recomposition without appetite suppression, CJC-1295 + Ipamorelin + AOD-9604 targets fat loss while building lean mass. All stacking should be supervised by a practitioner.
How does DNA testing help choose a weight loss peptide?
Specific genetic variants alter the receptors and metabolic pathways that weight loss peptides target. GLP1R rs6923761 predicts semaglutide response speed (58% difference between genotypes). PPARG rs1801282 predicts AOD-9604 effectiveness for fat mobilisation. A genetic peptide report tests these variants and ranks compounds by your predicted response.
Is AOD-9604 FDA approved for weight loss?
No. AOD-9604 completed Phase II trials showing statistically significant fat loss, but was not approved by the FDA as a weight loss drug. It is available through compounding pharmacies and peptide clinics. It is a modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis without GH's growth or diabetogenic effects.
What is MOTS-c and does it help with weight loss?
MOTS-c is a mitochondria-derived peptide that activates AMPK — the same metabolic pathway triggered by exercise and metformin. It improves insulin sensitivity and increases fatty acid oxidation. Human data is limited but the mechanism is strong. Response may vary by mitochondrial haplotype. It's considered an exercise mimetic rather than a traditional weight loss drug.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.